Chimeric Therapeutics Limited
CHMMF
$0.001
-$0.029-96.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 1.81M | 1.86M | -1.16M | -1.16M | 3.57M |
| Total Revenue | 1.81M | 1.86M | -1.16M | -1.16M | 3.57M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.81M | 1.86M | -1.16M | -1.16M | 3.57M |
| SG&A Expenses | 1.32M | 1.36M | 1.55M | 1.55M | 1.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.68M | 2.75M | 3.79M | 3.78M | 3.00M |
| Operating Income | -866.90K | -891.40K | -4.95M | -4.94M | 572.60K |
| Income Before Tax | -886.20K | -911.30K | -4.91M | -4.90M | 772.60K |
| Income Tax Expenses | 44.90K | 46.20K | 27.20K | 27.20K | -23.80K |
| Earnings from Continuing Operations | -931.20K | -957.50K | -4.93M | -4.92M | 796.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -931.20K | -957.50K | -4.93M | -4.92M | 796.40K |
| EBIT | -866.90K | -891.40K | -4.95M | -4.94M | 572.60K |
| EBITDA | -708.30K | -728.30K | -4.75M | -4.74M | 731.20K |
| EPS Basic | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.01B | 1.01B | 833.63M | 833.63M | 557.64M |
| Average Diluted Shares Outstanding | 1.01B | 1.01B | 833.63M | 833.63M | 557.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |